The latest issue of Nature Medicine features a recap (freely available) of a study performed by Deloitte about phase 2 clinical trials and the consequences of doing them right. Or wrong. Keep reading below for the full details.
|
Astex Pharma $ASTX will present two abstract this week at the EASL International Liver Congress relating to their preclinical fragment-based drug candidate for Hepatitis C virus (HCV) infection. The drug has for the first time been given an identifier (AT26983) signifying that a lead candidate has been selected for development. Here is the press release issued this morning. Visit the ASTX research page for info on all of Astex's clinical programs (most of the pipeline is cancer focused, and thus they will seek to out-license this HCV candidate early in development). See below for complete text of the two abstracts being presented on 4/20 poster session. Swiss pharma giant held their quarterly earnings call on April 12, 2012. See below for selected highlights related to the Illumina hostile takeover saga. Not mentioned much on the call was newly approved cancer drug ERIVEDGE which is licensed from Curis $CRIS - but sales since launch in late January were reported as being $5.5m for the quarter, meaning that royalties to Curis are miniscule at this point (most estimates I have seen indicate mid single digit royalties). Access the entire transcript at Morningstar. Check out all the companies I cover, with my new real-time valuation updates on the Stocks page. Ligand and partner GSK are presented the results of the second phase 3 trial of PROMACTA (eltrombopag) in hepatitis C virus (HCV) patients at the upcoming EASL meeting. GSK previewed the data at AASLD in the fall, and the disclosure of an imbalance in thromboembolic events and deaths sent LGND shares cratering to as low as ~10.50. LGND recovered to ask high as nearly 19 before settling back recently. The full abstract release today doesn't seem to be causing an undue LGND sell-off (down 4.6% on higher than average volume) on a bad market day for most biotechs. See below for the full abstract. Synta Pharma will have numerous presentations at the AACR cancer research meeting this week. See below for a couple abstracts on their elesclomol program. Visit HSP90 Central for a number of abstracts related to their HSP90 inhibitor ganetespib (STA-9090) |
Categories
All
Archives
January 2020
|
RSS Feed
